Trends in left ventricular assist device use and outcomes among Medicare beneficiaries, 2004-2011

Open Heart

Volumn 1, Issue 1, 2014, Pages

  Lampropulos, Julianna F ^a,b   Kim, Nancy ^a,b   Wang, Yun ^a,b,c   Desai, Mayur M ^a,d   Barreto Filho, José Augusto S ^a,e   Dodson, John A ^f   Dries, Daniel L ^b   Mangi, Abeel A ^b   Krumholz, Harlan M ^a,b,d,g  

^a YALE NEW HAVEN HOSPITAL   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d YALE UNIVERSITY   (United States)

^e FEDERAL UNIVERSITY OF SERGIPE   (Brazil)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g ROBERT WOOD JOHNSON FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; COST BENEFIT ANALYSIS; DEVICE APPROVAL; FEMALE; HEART FAILURE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MORTALITY; OUTCOME ASSESSMENT; PROSTHESIS IMPLANTATION; SURVIVAL RATE; SURVIVAL TIME; SURVIVOR; TREATMENT RESPONSE; TREND STUDY;

EID: 84984629800     PISSN: None     EISSN: 20533624     Source Type: Journal    
DOI: 10.1136/openhrt-2014-000109     Document Type: Article

References (29)

1. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001;345:1435-43.
2. US Food and Drug Administration. Department of Health and Human Services. Device Approvals and Clearances. http://www.accessdata.fda.gov/cdrh-docs/pdf6/p060040a.pdf (accessed 1 Oct 2013).
3. Centers for Medicare & Medicaid Services. Decision memo for ventricular assist devices as destination therapy (CAG-00119N). http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=79. (accessed 12 Jul 2013).
4. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46:e1-82.
5. National Heart, Lung and Blood Institute. Workshop, Meeting Summaries, Scientific Reports. http://www.nhlbi.nih.gov/meetings/workshops/nextgen-vads.htm. (accessed 12 Jul 2012).
6. Dowling RD, Park SJ, Pagani FD, et al. HeartMate VE LVAS design enhancements and its impact on device reliability. Eur J Cardiothorac Surg 2004;25:958-63.
7. Pagani FD, Long JW, Dembitsky WP, et al. Improved mechanical reliability of the HeartMate XVE left ventricular assist system. Ann Thorac Surg 2006;82:1413-18.
8. Hernandez AF, Shea AM, Milano CA, et al. Long-term outcomes and costs of ventricular assist devices among Medicare beneficiaries. JAMA 2008;300:2398-406.
9. Starling RC, Naka Y, Boyle AJ, et al. Results of the post-US Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol 2011;57:1890-8.
10. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009;361:2241-51.
11. Pagani FD, Miller LW, Russell SD, et al. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol 2009;54:312-21.
12. Khazanie P, Hammill BG, Patel CB, et al. Trends in the use and outcomes of ventricular assist devices among Medicare beneficiaries, 2006-2011. J Am Coll Cardiol 2014;63:1395-404.
13. Centers for Medicare & Medicaid Services. http://www.medicare.gov/sign-up-change-plans/medicare-health-plans/medicare-advantage-plans/private-fee-for-service-plans.html (accessed 28 May 2014).
14. Eicheldinger C, Bonito A. More accurate racial and ethnic codes for Medicare administrative data. Health Care Financ Rev 2008;29:27-42.
15. Krumholz HM, Wang Y, Mattera JA, et al. An administrative claims model suitable for profiling hospital performance based on 30-day mortality rates among patients with heart failure. Circulation 2006;113:1693-701.
16. Bratzler DW, Normand SL, Wang Y, et al. An administrative claims model for profiling hospital 30-day mortality rates for pneumonia patients. PLoS ONE 2011;6:e17401.
17. Keenan PS, Normand SL, Lin Z, et al. An administrative claims measure suitable for profiling hospital performance on the basis of 30-day all-cause readmission rates among patients with heart failure. Circ Cardiovasc Qual Outcomes 2008;1:29-37.
18. Krumholz HM, Lin Z, Drye EE, et al. An administrative claims measure suitable for profiling hospital performance based on 30-day all-cause readmission rates among patients with acute myocardial infarction. Circ Cardiovasc Qual Outcomes 2011;4:243-52.
19. Lindenauer PK, Normand SL, Drye EE, et al. Development, validation, and results of a measure of 30-day readmission following hospitalization for pneumonia. J Hosp Med 2011;6:142-50.
20. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:e391-479.
21. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics - 2014 update: a report from the American Heart Association. Circulation 2014;129:e28-292.
22. Kirklin JK, Naftel DC, Pagani FD, et al. Sixth INTERMACS annual report: a 10,000-patient database. J Heart Lung Transplant 2014;33:555-64.
23. Kirklin JK, Naftel DC, Kormos RL, et al. Fifth INTERMACS annual report: risk factor analysis from more than 6,000 mechanical circulatory support patients. J Heart Lung Transplant 2013;32:141-56.
24. Rogers JG, Aaronson KD, Boyle AJ, et al. Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. J Am Coll Cardiol 2010;55:1826-34.
25. Slaughter MS, Bostic R, Tong K, et al. Temporal changes in hospital costs for left ventricular assist device implantation. J Card Surg 2011;26:535-41.
26. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 2012;125:e2-220.
27. Kaiser Family Foundation. Medicare advantage 2010 data spotlight: plan enrollment patterns and trends. http://www.kff.org/medicare/upload/8080.pdf (accessed 12 Jul 2012).
28. Kirklin JK, Naftel DC, Kormos RL, et al. Third INTERMACS annual report: the evolution of destination therapy in the United States. J Heart Lung Transplant 2011;30:115-23.
29. Birman-Deych E, Waterman AD, Yan Y, et al. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care 2005;43:480-5.